SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).
The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive.
Related: Merck Shows Takeover Interest In Seagen: WSJ.
According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in 2023, 2024, and 2025 from that expected for standalone …

Full story available on Benzinga.com

Read More